Overview

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Status:
Active, not recruiting

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

Summary

This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborators:

AbbVie
German CLL Study Group

Treatments:

Chlorambucil
Obinutuzumab
Venetoclax